Biocompatibles
This article was originally published in The Gray Sheet
Executive Summary
British firm will return roughly $143.6 mil. ($1.01 per ordinary share) to shareholders following the March 18 acquisition of its stent manufacturing facility by Abbott Labs (1"The Gray Sheet" March 25, 2002, p. 3)...
You may also be interested in...
Abbott $235 Mil. Biocompatibles Stent Purchase Includes Royalties Up To 6%
Abbott's acquisition of the cardiovascular stent business of Biocompatibles International for $234.5 mil. in cash plus royalties will facilitate integration of Abbott's internally-developed, rapamycin analogue stent coating with Biocompatibles' BiodivYsio stent line
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.